earli
accur
diagnosi
lateonset
neonat
sepsi
lon
major
diagnost
challeng
neonatolog
lon
occur
frequent
preterm
lowbirthweight
vlbw
infant
newborn
surgic
condit
requir
prolong
parenter
nutrit
hospit
neonat
intens
care
unit
nicu
recent
multicent
survey
suggest
onefifth
vlbw
infant
least
episod
lateonset
cultureproven
sepsi
date
clinic
differenti
lon
includ
septicemia
mening
system
infectioninflamm
eg
necrot
enterocol
nec
noninfecti
condit
eg
acut
exacerb
bronchopulmonari
dysplasia
apnea
prematur
gastrointestin
dysmotil
remain
difficult
imposs
earli
stage
ill
test
biomark
accur
identifi
activ
infectioninflamm
includ
septicemia
nec
vulner
patient
would
provid
invalu
inform
diagnosi
manag
review
focus
properti
ideal
diagnost
marker
panel
biomark
infect
differ
categori
inflammatori
mediat
acut
phase
protein
chemokin
cytokin
cellsurfac
antigen
could
potenti
use
clinic
biomark
use
molecular
biogenet
techniqu
identif
pathogen
steril
bodi
fluid
author
also
discuss
recent
scientif
advanc
search
novel
biomark
infect
newborn
author
previous
propos
set
clinic
laboratori
criteria
assist
neonatologist
identifi
ideal
diagnost
marker
infect
although
financi
disclosur
author
financi
disclosur
fundament
principl
remain
unchang
continu
advanc
technolog
neonatologist
expect
clinic
inform
provid
biomark
box
summar
current
view
characterist
ideal
biomark
biomark
serv
guid
stop
antimicrobi
treatment
noninfect
infant
also
aid
decis
whether
start
antibiot
treatment
onset
nonspecif
clinic
sign
advanc
molecular
biogenet
techniqu
ideal
biomark
test
also
expect
pinpoint
precis
ident
categori
microorgan
caus
sepsi
inform
sever
infect
likelihood
progress
dissemin
intravascular
coagul
dic
would
also
provid
invalu
insight
clinician
target
infant
sepsi
need
urgent
treatment
intens
care
support
identif
pathogen
antibiot
suscept
profil
diseas
onset
would
also
contribut
enorm
acut
manag
identifi
specif
pathogen
categori
pathogen
eg
viral
bacteri
fungal
organ
gramposit
organ
vs
gramneg
organ
specif
speci
pathogen
monitor
diseas
progress
guid
antimicrobi
treatment
eg
bacteri
antibiot
resist
gene
detect
predict
diseas
sever
onset
infect
eg
identifi
type
virul
pathogen
predict
dic
onset
diseas
present
predict
prognosi
ie
mortal
stabl
compound
may
allow
adequ
time
window
specimen
collect
within
normal
work
hour
ie
sustain
increas
decreas
biomark
level
least
hour
easi
storag
specimen
without
signific
decomposit
activ
compound
laboratori
process
quantit
determin
biomark
concentr
automat
easi
method
measur
quick
turnaround
time
ie
specimen
collect
transport
laboratori
process
time
report
result
clinician
within
hour
small
volum
specimen
ie
ml
blood
daili
ondemand
avail
test
clinic
laboratori
lowcost
test
use
routin
measur
biochem
biomark
stabl
remain
significantli
upregul
downregul
bodi
fluid
compart
least
hour
even
commenc
appropri
antimicrobi
treatment
would
increas
chanc
true
posit
test
result
given
variabl
time
test
rel
onset
diseas
treatment
ideal
biomark
would
resist
decomposit
transport
storag
result
would
accur
reflect
infant
clinic
condit
time
specimen
sampl
properti
list
box
also
crucial
maxim
util
biomark
routin
diagnost
test
nicu
set
date
biomark
investig
key
proinflammatori
antiinflammatori
mediat
infectioninflammatori
cascad
major
disadvantag
nonspecif
biomark
tendenc
influenc
inflammatori
condit
induc
sepsi
tissu
injuri
surgeri
furthermor
local
infect
frequent
escap
detect
discoveri
new
biomark
key
blood
cultur
current
gold
standard
diagnos
septicemia
suboptim
newborn
infant
falseneg
result
common
small
volum
blood
sampl
intermitt
presenc
low
densiti
circul
pathogen
earli
stage
infect
pretreat
antibiot
exacerb
problem
hematolog
test
total
white
cell
count
differenti
white
cell
count
immatur
total
neutrophil
ratio
white
cell
morpholog
platelet
count
variou
hematolog
score
gener
consid
particularli
use
differenti
sepsisnec
noninfecti
condit
hematolog
test
insuffici
sensit
specif
guid
clinic
manag
particular
antibiot
treatment
hematolog
test
ratio
also
suboptim
complex
methodolog
requir
skill
technician
identifi
immatur
neutrophil
form
peripher
blood
smear
although
presenc
neutropenia
thrombocytopenia
suggest
sever
system
infect
noninfecti
condit
sever
lung
diseas
caus
thrombocytopenia
platelet
sequestr
hematolog
paramet
limit
diagnost
util
recent
studi
biomark
concentr
major
categori
mediat
acut
phase
protein
chemokin
proand
antiinflammatori
cytokin
cellsurfac
antigen
acut
phase
protein
creactiv
protein
crp
serum
amyloid
saa
procalcitonin
pct
extens
studi
crp
wide
use
mani
nicu
diagnosi
monitor
treatment
lon
nec
previous
report
crp
late
biomark
high
specif
neonat
sepsi
concentr
serum
crp
usual
elev
time
clinic
present
delay
hour
onset
symptom
although
crp
gener
consid
nonspecif
biomark
research
shown
high
specif
neonat
system
infect
preterm
infant
narrow
spectrum
diseas
compar
older
patient
noninfecti
inflammatori
condit
confound
diagnosi
sepsi
adult
patient
rheumatoid
arthriti
connect
tissu
diseas
inflammatori
bowel
diseas
occur
rare
neonat
therefor
signific
increas
serum
crp
concentr
like
associ
system
sepsi
bowel
inflammationnecrosi
secondari
nec
serial
measur
crp
concentr
particularli
use
biomark
lateonset
neonat
sepsi
rule
sepsi
persist
normal
level
hour
assist
decis
make
discontinu
antibiot
treatment
infant
equivoc
present
limit
applic
measur
crp
level
falseposit
falseneg
result
report
importantli
test
sensit
diagnos
local
infect
pneumonia
urinari
tract
infect
isol
lowgrad
fungal
central
nervou
system
infect
also
use
indic
surgeri
recent
immun
circul
level
tend
significantli
elev
event
studi
arnon
colleagu
compar
saa
crp
interleukin
il
suggest
saa
higher
sensit
within
first
hour
biomark
identif
lon
particular
sensit
crp
much
wors
earli
phase
infect
wherea
suboptim
hour
onset
specif
saa
compar
crp
throughout
clinic
cours
addit
anoth
studi
perform
investig
indic
mortal
infect
preterm
infant
invers
correl
circul
saa
hour
hour
studi
suggest
saa
may
better
biomark
crp
provid
vital
inform
prognosi
earli
cours
infect
pct
also
extens
studi
newborn
adult
kinet
pct
suggest
serum
concentr
begin
increas
hour
exposur
bacteri
product
peak
hour
remain
elev
least
hour
physiolog
increas
pct
level
first
hour
life
thought
secondari
gastrointestin
bacteri
colon
subsequ
transloc
endotoxin
bowel
wall
howev
substanti
increas
serum
pct
concentr
bacteri
infect
easili
differenti
minor
physiolog
increas
immedi
postnat
period
overal
diagnost
util
similar
acut
phase
reactant
although
studi
suggest
pct
may
superior
better
sensit
specif
identifi
lon
acut
phase
reactant
protein
haptoglobin
lactoferrin
neopterin
interainhibitor
protein
iaip
lipopolysaccharidebind
protein
lbp
compon
complement
pathway
eg
report
potenti
use
diagnost
biomark
particular
interest
focus
lbp
iaip
lbp
theoret
fill
diagnost
gap
earli
eg
late
biomark
eg
crp
chemic
kinet
recent
studi
demonstr
lbp
superior
sensit
neg
predict
valu
compar
pct
crp
diagnos
neonat
infect
infect
infant
also
shown
significantli
lower
iaip
level
noninfect
infant
nonetheless
latter
studi
iaip
rel
small
clinic
use
marker
confirm
time
base
current
evid
avail
test
clinic
laboratori
nicu
current
reli
serial
measur
crp
concentr
identif
infant
lon
chemokin
cytokin
extens
studi
past
decad
import
categori
mediat
proinflammatori
cytokin
antiinflammatori
cytokin
chemokin
interferonginduc
protein
rant
regul
upon
activ
normal
cell
express
secret
found
potenti
use
earli
diagnosi
lon
predict
sever
infect
onset
sepsi
present
proinflammatori
mediat
earli
warn
biomark
circul
level
rapidli
substanti
increas
infect
induc
product
crp
liver
surpris
upregul
preced
crp
sepsi
measur
conjunct
receptor
antagonist
may
help
predict
lon
day
clinic
manifest
becom
evid
longer
halflif
compar
cytokin
potenti
increas
util
sepsi
biomark
short
halflif
circul
level
decreas
precipit
back
baselin
noninfecti
state
within
hour
appropri
treatment
chemokin
follow
similar
time
cours
characterist
greatli
limit
role
clinic
use
biomark
across
phase
sepsi
although
may
util
earli
present
therapi
quantit
intracellular
treat
whole
blood
sampl
deterg
lyse
white
blood
cell
may
lengthen
window
opportun
obtain
blood
sampl
enhanc
diagnost
util
chemokin
cytokin
tumor
necrosi
factor
tnf
monokin
induc
interferong
monocyt
chemoattract
protein
mcp
growthrel
oncogen
significantli
upregul
infect
nec
wherea
rant
downregul
case
concomit
thrombocytopenia
util
diagnost
biomark
promis
mention
earlier
anoth
import
group
inflammatori
mediat
antiinflammatori
cytokin
transform
growth
factor
b
import
prevent
exagger
proinflammatori
respons
sepsi
elev
antiinflammatori
proinflammatori
tnfa
ratio
adult
patient
infect
associ
advers
outcom
increas
ratio
also
associ
sever
lon
vlbw
infant
anoth
studi
algorithm
use
sequenti
measur
rant
clinic
present
shown
sensit
reliabl
predict
develop
dic
sever
infect
infant
inform
crucial
identifi
serious
ill
infant
need
urgent
treatment
intens
care
support
may
also
assist
counsel
parent
earli
stage
ill
magnitud
balanc
imbal
proinflammatori
antiinflammatori
respons
crucial
reflect
sever
sepsi
may
play
import
role
predict
morbid
mortal
despit
favor
properti
chemokin
cytokin
assess
use
mediat
success
integr
routin
clinic
practic
highcost
nonautom
laborintens
methodolog
lack
ondemand
test
clinic
laboratori
major
obstacl
prevent
evolut
cytokin
routin
diagnost
test
nicu
set
advanc
flow
cytometr
technolog
pave
way
easi
detect
cellsurfac
antigen
circul
inflammatori
cell
includ
neutrophil
lymphocyt
monocyt
natur
killer
nk
cell
specif
cellsurfac
antigen
express
larg
quantiti
soon
target
cell
activ
microbi
product
bacteri
toxin
mani
cellsurfac
antigen
investig
relat
neonat
sepsi
promis
one
neutrophil
neutrophilmonocyt
antigen
express
low
densiti
nonactiv
white
blood
cell
surfac
bacteri
fungal
infect
nec
antigen
substanti
upregul
concentr
cell
surfac
accur
quantit
measur
flow
cytometri
author
find
suggest
neutrophil
sensit
biomark
diagnosi
earlyonset
sepsi
lon
upregul
significantli
preced
crp
recent
neutrophil
also
demonstr
good
indic
intraabdomin
sepsi
includ
nec
bowel
perfor
periton
expect
test
unabl
differenti
system
infect
intraabdomin
sepsisinflamm
lam
hs
colleagu
unpublish
data
neutrophil
also
suggest
sensit
biomark
earlyonset
neonat
infect
subsequ
studi
daili
surveil
show
neutrophilmonocyt
could
reveal
evid
infect
day
clinic
manifest
find
repeat
would
requir
valid
larger
studi
unlik
result
variabl
find
consist
center
express
also
influenc
noninfecti
condit
respiratori
distress
syndrom
author
compar
neutrophil
neutrophil
within
studi
found
significantli
better
util
diagnos
lon
nec
cellsurfac
antigen
includ
nk
cell
lymphocyt
elabor
panel
leukocyt
surfac
antigen
includ
also
investig
none
show
better
diagnost
util
advantag
flow
cytometri
includ
small
blood
volum
ml
whole
blood
rapid
turnaround
time
hour
wide
window
opportun
blood
sampl
abil
perform
test
ad
hoc
basi
disadvantag
flow
cytometri
requir
skill
technician
carri
multistep
measur
semiautomat
flow
cytometri
consid
routin
diagnost
evalu
nicu
quantit
polymeras
chain
reaction
qpcr
rapid
test
detect
bacteri
dna
steril
bodi
fluid
includ
blood
pleural
periton
cerebrospin
fluid
desir
convent
microbiolog
method
fail
detect
organ
molecular
techniqu
fluoresc
situ
hybrid
substanti
reduc
time
requir
identifi
organ
isol
cultur
reduct
much
hour
bacteri
isol
hour
yeast
directli
detect
pathogen
dna
attract
especi
target
fastidi
slowgrow
organ
molecular
techniqu
focu
identif
singl
speci
bacteria
particularli
use
intens
care
set
ideal
test
would
encompass
wide
varieti
pathogen
commonli
encount
nicu
use
probebas
gramspecif
qpcr
rapid
detect
differenti
gramneg
gramposit
bloodstream
infect
attempt
recent
studi
test
high
specif
posit
predict
valu
especi
identif
gramneg
organ
although
test
sensit
enough
rule
sepsi
particularli
use
rule
sepsi
high
specif
thu
posit
test
result
would
strongli
indic
need
full
cours
antimicrobi
treatment
despit
neg
cultur
pathogen
identif
gramspecif
sepsi
would
serv
use
guid
prescrib
appropri
effect
antibiot
predict
virul
caus
pathogen
sever
infect
major
limit
identifi
studi
uncommon
organ
includ
genet
sequenc
primerprob
would
escap
detect
gramposit
organ
fungi
elabor
cell
wall
structur
resili
digest
destruct
pose
major
problem
dna
extract
use
molecular
diagnost
detect
bloodstream
infect
neonat
shown
promis
technic
challeng
time
requir
convent
method
isol
pathogen
result
signific
delay
least
sever
day
vital
inform
antibiot
sensit
becom
avail
recent
investig
use
microarraybas
techniqu
demonstr
possibl
detect
bacteri
antibiot
resist
gene
within
hour
studi
aim
identifi
gene
encod
resist
firstlin
antibiot
critic
import
choos
empir
therapi
infant
suspect
sepsi
concentr
cytokin
chemokin
within
bloodstream
often
fulli
reflect
infect
inflammatori
process
ongo
within
patient
recent
investig
focus
possibl
identifi
gene
upregul
infect
one
studi
measur
whole
blood
mrna
concentr
suggest
level
mrna
elev
infant
perinat
asphyxia
wherea
mrna
level
elev
infant
perinat
infect
detect
tissuespecif
mrna
could
potenti
use
basi
develop
diseasespecif
biomark
neonat
mass
spectrometrybas
proteom
profil
technolog
surfaceenhanc
laser
desorptionion
use
identifi
host
respons
protein
signatur
diagnosi
wide
varieti
patholog
condit
diseas
sever
acut
respiratori
syndrom
intraamniot
inflamm
neonat
sepsi
date
clinic
studi
involv
acut
phase
protein
chemokin
cytokin
cellsurfac
antigen
select
key
mediat
antigen
infectioninflammatori
cascad
use
tradit
candid
approach
test
diagnost
util
lon
convent
approach
greatli
confin
restrict
search
biomark
known
mediat
protein
cascad
contrast
proteom
technolog
hypothesisfre
approach
potenti
discov
novel
host
respons
biomark
diagnosi
lon
nec
preterm
infant
author
recent
complet
proteom
project
discov
one
known
protein
one
novel
lipoprotein
earli
accur
identif
infant
sepsi
nec
new
proteom
sepsi
score
deriv
two
biomark
would
guid
frontlin
neonatologist
whether
start
antibiot
treatment
time
clinic
present
stop
therapi
within
hour
commenc
score
ensur
patient
safeti
neg
predict
valu
would
preclud
signific
proport
true
nonsepsi
case
receiv
antibiot
unnecessarili
earli
withdraw
treatment
proteom
technolog
may
assist
identifi
novel
biochem
pathway
associ
infect
power
tool
biomark
discoveri
demonstr
technolog
compet
appli
prematur
infant
limit
proteom
protein
low
plasma
concentr
chemokin
cytokin
may
easili
detect
method
addit
stringent
protocol
elabor
studi
design
requir
ensur
protein
identifi
genuin
repres
specif
condit
investig
date
singl
ideal
diagnost
biomark
lon
identifi
tabl
summar
pro
con
differ
categori
inflammatori
mediat
biomark
lateonset
neonat
sepsi
test
clinic
evalu
ideal
biomark
panel
would
provid
inform
facilit
earli
diagnosi
predict
sever
infect
outcom
onset
clinic
sign
symptom
exampl
first
suspicion
sepsi
proteom
sepsi
score
earli
biomark
includ
neutrophil
could
use
decid
whether
start
antimicrobi
treatment
also
give
forewarn
sever
sepsi
likelihood
develop
dic
hour
repeat
proteom
sepsi
score
neutrophil
could
facilit
decis
discontinu
antibiot
nonsepsi
case
thereaft
serial
crp
level
measur
may
use
monitor
progress
develop
late
complic
molecular
diagnost
could
consid
highli
suspect
case
sepsi
nec
neg
blood
cultur
test
steril
bodi
fluid
provid
microbiolog
inform
obtain
nonspecif
test
clinic
research
team
primarili
respons
identifi
favor
biomark
confirm
clinic
laboratori
properti
biomark
typic
hospit
nicu
set
one
main
reason
favor
biomark
becom
routin
clinic
test
autom
method
measur
develop
industri
sector
academicindustri
partnership
essenti
success
develop
new
clinic
use
diagnost
biomark
new
molecular
biogenet
technolog
rapidli
advanc
nonspecif
biomark
would
like
replac
specif
test
could
pinpoint
precis
condit
ie
differenti
septicemia
nec
focal
infect
pneumonia
provid
vital
inform
pathogen
antibiot
resist
profil
within
hour
clinic
present
